Search Results for "activate"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for activate. Results 651 to 660 of 1334 total matches.
Cardiovascular Effects of Some Antidiabetic Drugs
The Medical Letter on Drugs and Therapeutics • Aug 14, 2017 (Issue 1527)
for unstable angina,
compared to placebo or active comparators.19
In a case-control analysis of >1 million ...
...
Romosozumab (Evenity) for Postmenopausal Osteoporosis
The Medical Letter on Drugs and Therapeutics • Jun 03, 2019 (Issue 1573)
/beta-catenin signaling and activation
of osteoblast function. Inhibition of sclerostin by
romosozumab ...
The FDA has approved romosozumab-aqqg (Evenity –
Amgen), a sclerostin inhibitor, for once-monthly
subcutaneous (SC) treatment of osteoporosis in
postmenopausal women who are at high risk
for fracture (history of osteoporotic fracture or
multiple risk factors for fracture) or who have failed
or cannot tolerate other drugs for this indication.
Romosozumab is the first sclerostin inhibitor to be
approved in the US and the third drug for treatment of
postmenopausal osteoporosis that stimulates bone
formation; the parathyroid hormone (PTH) receptor
agonists abaloparatide (Tymlos) and...
Advice for Travelers
The Medical Letter on Drugs and Therapeutics • Oct 07, 2019 (Issue 1582)
activities who cannot risk the
temporary incapacitation associated with diarrhea,
might benefit ...
Patients who receive pretravel advice can reduce their
risk for many travel-related conditions. Vaccines recommended
for travelers are reviewed in a separate issue.
Three Drugs for Atopic Dermatitis (Adbry, Cibinqo, and Rinvoq)
The Medical Letter on Drugs and Therapeutics • Apr 03, 2023 (Issue 1673)
by CYP3A4
two active metabolites
Elimination Not applicable Primarily as metabolites in urine Primarily ...
The subcutaneously injected interleukin-13 (IL-13)
antagonist tralokinumab-ldrm (Adbry – Leo) and
the oral Janus kinase (JAK) inhibitors abrocitinib
(Cibinqo – Pfizer) and upadacitinib (Rinvoq – Abbvie)
have been approved by the FDA for treatment of
moderate to severe atopic dermatitis.
Med Lett Drugs Ther. 2023 Apr 3;65(1673):51-5 doi:10.58347/tml.2023.1673b | Show Introduction Hide Introduction
Nabilone And Other Antiemetic For Cancer Patients
The Medical Letter on Drugs and Therapeutics • Jan 01, 1988 (Issue 756)
cannabinoid chemically related to tetrahydrocannabinol
(THC), the main active ingredient in marijuana ...
Nabilone (Cesamet - Lilly), a synthetic cannabinoid chemically related to tetrahydrocannabinol (THC), the main active ingredient in marijuana, was recently marketed in the USA for oral treatment of nausea and vomiting associated with cancer chemotherapy. Oral THC itself, known generically as dronabinol (Marinol), is also commercially available as an antiemetic for cancer patients (Medical Letter, 27:97, 1985). Other drugs used for this purpose include metoclopramide (Reglan - Medical Letter, 24:67, 1982), prochlorperazine (Compazine; and others), haloperidol (Haldol; and others), and...
Ketorolac Tromethamine
The Medical Letter on Drugs and Therapeutics • Aug 24, 1990 (Issue 825)
OF ACTION — Like other NSAIDs, ketorolac has anti-inflammatory, analgesic,
and antipyretic activity ...
Ketorolac (kee'; toe role ak) tromethamine (Toradol), manufactured by Syntex but also marketed by Roche, is the first parenteral nonsteroidal anti-inflammatory drug (NSAID) to become available for analgesic use in the USA. Parenteral indomethacin (Indocin I.V.) has been marketed here since 1985, but only for treatment of patent ductus arteriosus in newborn infants. Other parenteral NSAIDs are available in other parts of the world, but low potency, poor aqueous solubility, and substantial tissue irritation on injection have limited their usefulness. Ketorolac has been approved by the US ...
Foscarnet
The Medical Letter on Drugs and Therapeutics • Jan 10, 1992 (Issue 861)
).
ANTIVIRAL ACTIVITY — Foscarnet inhibits the DNA polymerase of human herpesviruses and
the reverse ...
Phosphonoformic acid or foscarnet (Foscavir - Astra), a synthetic antiviral drug, has now been approved by the US Food and Drug Administration for intravenous (IV) treatment of cytomegalovirus (CMV) retinitis in patients with AIDS. CMV retinitis occurs in up to 30% of patients with AIDS and often causes blindness (MD de Smet and RB Nussenbatt, JAMA, 266:3019, Dec 4, 1991).
Aspirin for Prevention of Myocardial Infarction
The Medical Letter on Drugs and Therapeutics • Feb 17, 1995 (Issue 942)
activity in platelets, preventing formation of thromboxane A
2
, which stimulates platelet aggregation ...
Aspirin is now widely used for antithrombotic prophylaxis in patients who have had angina pectoris or a myocardial infarction and has also been tried in healthy people to prevent myocardial infarction. Recent studies have focused on increasingly lower doses of the drug. The use of aspirin in patients who have had transient ischemic attacks or strokes will not be discussed here.
Radiofrequency Catheter Ablation for Treatment of Cardiac Arrhythmias
The Medical Letter on Drugs and Therapeutics • Apr 26, 1996 (Issue 973)
-frequency alternating electrical current) passes from an active electrode at the catheter
tip to a passive ...
In recent years, selective destruction of cardiac tissue by radiofrequency energy has become a routine procedure for treatment of some types of cardiac arrhythmias, particularly supraventricular tachycardias (MM Scheinman, Pacing Clin Electrophysiol, 18:1474, 1995).
Troglitazone for Non-Insulin-Dependent Diabetes Mellitus
The Medical Letter on Drugs and Therapeutics • May 23, 1997 (Issue 1001)
resistance by binding to nuclear peroxisome proliferator-activated receptors
(PPARs) involved ...
Troglitazone (Rezulin - Parke-Davis), the first of a new class of thiazolidinedione derivatives ('glitazones') for diabetes, has been marketed for oral treatment of noninsulin- dependent diabetes mellitus (NIDDM) in patients who take more than 30 units of insulin daily and still have a glycosylated hemoglobin concentration (HbA1c) of 8.5% or higher.